All In MedTech

Device Trial Radar · NCT04760002

DANish Patients With Atrial Fibrillation and Sleep Apnea Prevalence by Night Owl

Danish Patients With Atrial Fibrillation and Sleep Apnea Prevalence by Night Owl

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

126

Actual

Start

Jan 25, 2021

Primary completion

Jan 1, 2023

Study completion Jan 1, 2023

Sponsor

Lead sponsor
Herlev and Gentofte HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sygekassernes Helsefond
First posted
Feb 18, 2021

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 90 years

Summary

As written by the sponsor on the registry.

A project of the feasibility of using NightOwl to detect the prevalence of obstructive sleep apnea (OSA) in patients with atrial fibrillation (AF). The long-term aim is to use the device to screen for OSA in a randomized clinical trial in AF patients undergoing ablation and/or a randomized trial of AF patients undergoing cardioversion.

Conditions

  • Obstructive Sleep Apnea

Interventions

  • NightOwlDevice

    The NightOwl consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl software. It is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl sensor acquires accelerometer data and reflectancebased photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prevalence of obstructive sleep apnea in atrial fibrillation patientsTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Herlev-Gentofte Hospital

    Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.